PIII Pengajuan SEC - P3 Health Partners Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

1832511

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to P3 Health Partners Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

August 29, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 27, 2025 P3 Health Partner UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 27, 2025 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction of incorporation) (Commission
August 29, 2025	EX-10.1	TENTH AMENDMENT TO TERM LOAN AGREEMENT Exhibit 10.1 TENTH AMENDMENT TO TERM LOAN AGREEMENT THIS TENTH AMENDMENT TO TERM LOAN AGREEMENT (this “Agreement”), dated as of August 27, 2025, is entered into among P3 HEALTH GROUP, LLC, a Delaware limited liability company (“Borrower”) (formerly known as FAC MERGER SUB LLC, successor by merger to P3 HEALTH GROUP HOLDINGS, LLC), the Subsidiary Guarantors party hereto, the Lenders party hereto an
August 14, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40033 P3 Health Partners In
August 14, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 14, 2025 P3 Health Partner UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 14, 2025 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction of incorporation) (Commission
August 14, 2025	EX-99.1	P3 Health Partners Announces Second Quarter 2025 Results Core Business Demonstrates Strength with Flat Medical Cost Trends Despite Industry Inflation $120-$170 Million in Additional EBITDA Opportunities Identified for 2026 Adjusted Full Year Guidance Exhibit 99.1 P3 Health Partners Announces Second Quarter 2025 Results Core Business Demonstrates Strength with Flat Medical Cost Trends Despite Industry Inflation $120-$170 Million in Additional EBITDA Opportunities Identified for 2026 Adjusted Full Year Guidance Reflects Prior Period Headwinds Management to Host Conference Call and Webcast August 14, 2025 at 4:30 PM ET HENDERSON, NV—August 14, 20
July 9, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 2, 2025 P3 Health Partners I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 2, 2025 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction of incorporation) (Commission Fi
June 10, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 4, 2025 P3 Health Partners I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 4, 2025 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction of incorporation) (Commission Fi
June 3, 2025	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 29, 2025 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction of incorporation) (Commission Fi
June 3, 2025	EX-10.4	Ninth Amendment to Term Loan Agreement, dated as of May 29, 2025, by and among P3 Health Group, LLC, as borrower, the Subsidiary Guarantors party thereto, the Lenders party thereto and CRG Servicing LLC, as administrative agent and collateral agent. Exhibit 10.4 NINTH AMENDMENT TO TERM LOAN AGREEMENT THIS NINTH AMENDMENT TO TERM LOAN AGREEMENT (this “Agreement”), dated as of May 29, 2025, is entered into among P3 HEALTH GROUP, LLC, a Delaware limited liability company (“Borrower”) (formerly known as FAC MERGER SUB LLC, successor by merger to P3 HEALTH GROUP HOLDINGS, LLC), the Subsidiary Guarantors party hereto, the Lenders party hereto and C
June 3, 2025	EX-10.2	Warrant Agreement, dated May 29, 2025, by and among P3 Health Group, LLC, P3 Health Partners Inc. and VBC Growth SPV 5, LLC. EX-10.2 3 piii-20250529xex102warrants.htm EX-10.2 Exhibit 10.2 THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION ST
June 3, 2025	EX-10.1	Unsecured Promissory Note, dated May 29, 2025, by and between P3 Health Group, LLC and VBC Growth SPV 5, LLC. Exhibit 10.1 THIS UNSECURED PROMISSORY NOTE (AS AMENDED, RESTATED OR OTHERWISE MODIFIED FROM TIME TO TIME, THIS “NOTE”) AND ANY SECURITIES WHICH MAY BE ISSUED BY THE COMPANY (AS DEFINED BELOW) UNDER ITS TERMS HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CON
June 3, 2025	EX-10.3	Subordination Agreement, dated May 29, 2025, by and among P3 Health Group, LLC, CRG Servicing LLC and VBC Growth SPV 5, LLC. Exhibit 10.3 SUBORDINATION AGREEMENT This Subordination Agreement (this “Agreement”) is made as of May 29, 2025 among CRG Servicing LLC, a Delaware limited liability company (“Senior Agent”), and VBC Growth SPV 5, LLC, a Delaware limited liability company (“Subordinated Creditor”). RECITALS: A. P3 Health Group, LLC, a Delaware limited liability company (“Borrower”), intends to issue in favor of Su
May 15, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40033 P3 Health Partners I
May 15, 2025	EX-99.1	P3 Health Partners Announces First Quarter 2025 Results Affirming 2025 guidance Management to Host Conference Call and Webcast May 15, 2025 at 4:30 PM ET Exhibit 99.1 P3 Health Partners Announces First Quarter 2025 Results Affirming 2025 guidance Management to Host Conference Call and Webcast May 15, 2025 at 4:30 PM ET HENDERSON, NV—May 15, 2025—P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its financial results for the first quarter ended M
May 15, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2025 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction of incorporation) (Commission Fi
April 29, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amend TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 18, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 17, 2025	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 11, 2025 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction of incorporation) (Commission
April 17, 2025	EX-3.1	Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Company. Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF P3 HEALTH PARTNERS INC. P3 Health Partners Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follows: FIRST: That, at a meeting of the Board of Directors of the Corporation, resolutions were dul
April 4, 2025	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 4, 2025 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction of incorporation) (Commission F
April 3, 2025	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 31, 2025 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction of incorporation) (Commission
April 1, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107.1 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) P3 HEALTH PARTNERS INC. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee Equity Class A common
April 1, 2025	S-8	As filed with the Securities and Exchange Commission on March 31, 2025 As filed with the Securities and Exchange Commission on March 31, 2025 Registration No.
March 28, 2025	EX-10.34	dated November 30, 2024, by and between P3 Health Group, LLC and VBC Growth SPV 2, LLC. Execution Version FIRST AMENDMENT TO UNSECURED PROMISSORY NOTE THIS FIRST AMENDMENT TO UNSECURED PROMISSORY NOTE (this “Agreement”), dated as of November 30, 2024, is entered into between P3 HEALTH GROUP, LLC, a Delaware limited liability company (“Company”) and VBC Growth SPV 2, LLC, a Delaware limited liability company (“Holder”).
March 28, 2025	EX-19	P3 Health Partners, I P3 HEALTH PARTNERS INC. INSIDER TRADING POLICY Federal and state laws prohibit trading in the securities of a company while in possession of material nonpublic information and in breach of a duty of trust or confidence. These laws also prohibit anyone who is aware of material nonpublic information from providing this information to others who may trade. Violating such laws can undermine investor t
March 28, 2025	EX-10.51	0, 2024, by and among P3 Health Group, LLC, as borrower, the Subsid Execution Version FIFTH AMENDMENT TO TERM LOAN AGREEMENT THIS FIFTH AMENDMENT TO TERM LOAN AGREEMENT (this “Agreement”), dated as of November 30, 2024, is entered into among P3 HEALTH GROUP, LLC, a Delaware limited liability company (“Borrower”) (formerly known as FAC MERGER SUB LLC, successor by merger to P3 HEALTH GROUP HOLDINGS, LLC), the Subsidiary Guarantors party hereto, the Lenders party hereto and CRG SERVICING LLC, as administrative agent and collateral agent (the “Agent”).
March 28, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40033 P3 Health Partners Inc. (
March 27, 2025	EX-99.1	P3 Health Partners Announces Fourth Quarter and Full Year 2024 Results Revenue increased 18% year-over-year to $1.50 billion Affirming 2025 guidance Management to Host Conference Call and Webcast March 27, 2025 at 4:30 PM ET Exhibit 99.1 P3 Health Partners Announces Fourth Quarter and Full Year 2024 Results Revenue increased 18% year-over-year to $1.50 billion Affirming 2025 guidance Management to Host Conference Call and Webcast March 27, 2025 at 4:30 PM ET HENDERSON, NV—March 27, 2025—P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management com
March 27, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 27, 2025 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction of incorporation) (Commission
March 3, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amend TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
February 20, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amend TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
February 18, 2025	EX-10.2	Warrant Agreement, dated February 13, 2025, by and among P3 Health Group, LLC, P3 Health Partners Inc. and VBC Growth SPV 4, LLC. Exhibit 10.2 THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO CERTAIN EXC
February 18, 2025	EX-10.1	Unsecured Promissory Note, dated February 13, 2025, by and between P3 Health Group, LLC and VBC Growth SPV 4, LLC. Exhibit 10.1 THIS UNSECURED PROMISSORY NOTE (AS AMENDED, RESTATED OR OTHERWISE MODIFIED FROM TIME TO TIME, THIS “NOTE”) AND ANY SECURITIES WHICH MAY BE ISSUED BY THE COMPANY (AS DEFINED BELOW) UNDER ITS TERMS HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CON
February 18, 2025	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 13, 2025 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction of incorporation) (Commissi
February 18, 2025	EX-10.4	Seventh Amendment to Term Loan Agreement, dated as of February 13, 2025, by and among P3 Health Group, LLC, as borrower, the Subsidiary Guarantors party thereto, the Lenders party thereto and CRG Servicing LLC, as administrative agent and collateral agent. Exhibit 10.4 SEVENTH AMENDMENT TO TERM LOAN AGREEMENT THIS SEVENTH AMENDMENT TO TERM LOAN AGREEMENT (this “Agreement”), dated as of February 13, 2025, is entered into among P3 HEALTH GROUP, LLC, a Delaware limited liability company (“Borrower”) (formerly known as FAC MERGER SUB LLC, successor by merger to P3 HEALTH GROUP HOLDINGS, LLC), the Subsidiary Guarantors party hereto, the Lenders party her
February 18, 2025	EX-10.3	Subordination Agreement, dated February 13, 2025, by and among P3 Health Group, LLC, CRG Servicing LLC and VBC Growth SPV 4, LLC. Exhibit 10.3 SUBORDINATION AGREEMENT This Subordination Agreement (this “Agreement”) is made as of February 13, 2025 among CRG Servicing LLC, a Delaware limited liability company (“Senior Agent”), and VBC Growth SPV 4, LLC, a Delaware limited liability company (“Subordinated Creditor”). RECITALS: A. P3 Health Group, LLC, a Delaware limited liability company (“Borrower”), intends to issue in favor
February 13, 2025	EX-99.1	P3 Health Partners Provides Preliminary 2025 Guidance and Announces Proposed Financing Transaction Company provides preliminary 2025 guidance and advance notification of a proposed financing transaction to provide a $30 million unsecured promissory n Exhibit 99.1 P3 Health Partners Provides Preliminary 2025 Guidance and Announces Proposed Financing Transaction Company provides preliminary 2025 guidance and advance notification of a proposed financing transaction to provide a $30 million unsecured promissory note HENDERSON, NV—February 13, 2025—P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered, physician-led pop
February 13, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 13, 2025 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction of incorporation) (Commissi
December 17, 2024	EX-10.3	Subordination Agreement, dated December 12, 2024, by and among P3 Health Group, LLC, CRG Servicing Exhibit 10.3 SUBORDINATION AGREEMENT This Subordination Agreement (this “Agreement”) is made as of December 12, 2024 among CRG Servicing LLC, a Delaware limited liability company (“Senior Agent”), and VBC Growth SPV 3, LLC, a Delaware limited liability company (“Subordinated Creditor”). RECITALS: A. P3 Health Group, LLC, a Delaware limited liability company (“Borrower”), intends to issue in favor
December 17, 2024	EX-10.1	Unsecured Promissory Note, dated December 12, 2024, by and between P3 Health Exhibit 10.1 THIS UNSECURED PROMISSORY NOTE (AS AMENDED, RESTATED OR OTHERWISE MODIFIED FROM TIME TO TIME, THIS “NOTE”) AND ANY SECURITIES WHICH MAY BE ISSUED BY THE COMPANY (AS DEFINED BELOW) UNDER ITS TERMS HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CON
December 17, 2024	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 12, 2024 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction of incorporation) (Commissi
December 17, 2024	EX-10.5	Unsecured Promissory Note, dated December 12, 2024, by and between P3 Health Group, LLC and VBC Growth SPV Exhibit 10.5 THIS UNSECURED PROMISSORY NOTE (AS AMENDED, RESTATED OR OTHERWISE MODIFIED FROM TIME TO TIME, THIS “NOTE”) AND ANY SECURITIES WHICH MAY BE ISSUED BY THE COMPANY (AS DEFINED BELOW) UNDER ITS TERMS HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CON
December 17, 2024	EX-10.2	Warrant Agreement, dated December 12, 2024, by and among P3 Health Group, LLC, P3 Health Partners Inc. and VBC Growth SPV 3, LLC. Exhibit 10.2 THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO CERTAIN EXC
December 17, 2024	EX-10.6	Subordination Agreement, dated December 12, 2024, by and among P3 Health Group, LLC, CRG Servicing LLC and VBC Growth SPV Exhibit 10.6 SUBORDINATION AGREEMENT This Subordination Agreement (this “Agreement”) is made as of December 12, 2024 among CRG Servicing LLC, a Delaware limited liability company (“Senior Agent”), and VBC Growth SPV LLC, a Delaware limited liability company (“Subordinated Creditor”). RECITALS: A. P3 Health Group, LLC, a Delaware limited liability company (“Borrower”), intends to issue in favor of
December 17, 2024	EX-10.4	Sixth Amendment to Term Loan Agreement, dated as of December 12, 2024, by and among P3 Health Group, LLC, as borrower, the Subsidiary Guarantors party thereto, the Lenders party thereto and CRG Servicing LLC, as administrative agent and collateral agent. Exhibit 10.4 SIXTH AMENDMENT TO TERM LOAN AGREEMENT AND CONSENT THIS SIXTH AMENDMENT TO TERM LOAN AGREEMENT AND CONSENT (this “Agreement”), dated as of December 12, 2024, is entered into among P3 HEALTH GROUP, LLC, a Delaware limited liability company (“Borrower”) (formerly known as FAC MERGER SUB LLC, successor by merger to P3 HEALTH GROUP HOLDINGS, LLC), the Subsidiary Guarantors party hereto, t
December 17, 2024	EX-10.7	Second Amended and Restated Letter Agreement, dated December 12, 2024, by and among P3 Health Partners Inc., Chicago Pacific Founders GP, L.P. and Chicago Pacific Founders GP III, L.P. Exhibit 10.7 SECOND AMENDED AND RESTATED LETTER AGREEMENT This SECOND AMENDED AND RESTATED LETTER AGREEMENT (this “Agreement”) is entered into as of December 12, 2024 by and among P3 Health Partners Inc., a Delaware corporation (the “Company”), Chicago Pacific Founders GP, L.P., a Delaware limited partnership (“CPF GP I”), and Chicago Pacific Founders GP III, L.P., a Delaware limited partnership (
November 14, 2024	SC 13G	PIII / P3 Health Partners Inc. / Alyeska Investment Group, L.P. Passive Investment SC 13G 1 alyeska-piii093024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* P3 Health Partners Inc. (Name of Issuer) Class A common stock, par value $0.0001 per share (Title of Class of Securities) 744413105 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Che
November 12, 2024	EX-10.3	Restricted Stock Unit Agreement under the 2021 Incentive Award Plan, by and between P3 Health Partners Inc. and Leif Pedersen Exhibit 10.3 P3 HEALTH PARTNERS INC. 2021 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE P3 Health Partners Inc., a Delaware corporation (the “Company”), has granted to the participant listed below (“Participant”) the Restricted Stock Units (the “RSUs”) described in this Restricted Stock Unit Grant Notice (this “Grant Notice”), subject to the terms and conditions of the P3 Health Partners
November 12, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 12, 2024 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction of incorporation) (Commissi
November 12, 2024	EX-99.1	P3 Health Partners Announces Third Quarter 2024 Results Revenue increased 26% year-over-year to $362.1 million Third quarter results were affected by lower risk adjustments, higher medical expenses in the current year, and retroactive adjustments Exe Exhibit 99.1 P3 Health Partners Announces Third Quarter 2024 Results Revenue increased 26% year-over-year to $362.1 million Third quarter results were affected by lower risk adjustments, higher medical expenses in the current year, and retroactive adjustments Executing key 2025 initiatives with a focus on improvements in profitability metrics Management to Host Conference Call and Webcast November
November 12, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40033 P3 Health Partne
November 12, 2024	EX-10.2	Stock Option Agreement under the 2021 Incentive Award Plan, by and between P3 Health Partners Inc. and Leif Pedersen Exhibit 10.2 P3 HEALTH PARTNERS INC. 2021 INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE P3 Health Partners Inc., a Delaware corporation (the “Company”) has granted to the participant listed below (“Participant”) the stock option (the “Option”) described in this Stock Option Grant Notice (the “Grant Notice”), subject to the terms and conditions of the P3 Health Partners Inc. 2021 Incentive Award P
November 12, 2024	EX-10.1	Offer Letter Agreement, dated as of Exhibit 10.1 July 23, 2024 Re: Leif Pedersen Offer Letter for P3 Health Partners Dear Leif, It is with great pleasure that we extend this invitation to join P3 as its next Chief Financial Officer (CFO). We believe we are building a remarkable team of thought leaders in healthcare and are thrilled to invite you to be part of it. The commitment and conviction you have demonstrated about the importan
November 8, 2024	SC 13D/A	PIII / P3 Health Partners Inc. / Chicago Pacific Founders UGP, LLC - AMENDMENT NO. 3 TO SCHEDULE 13D Activist Investment SC 13D/A 1 ea0218790-13da3chicagop3.htm AMENDMENT NO. 3 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* P3 Health Partners Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 744413 105 (CUSIP Number) Michael J. Wilson Chief Financial
August 29, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 29, 2024 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction of incorporation) (Commission
August 7, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 7, 2024 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction of incorporation) (Commission
August 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40033 P3 Health Partners In
August 7, 2024	EX-99.1	P3 Health Partners Announces Second Quarter 2024 Results Management to Host Conference Call and Webcast August 7, 2024 at 4:30 PM ET Exhibit 99.1 P3 Health Partners Announces Second Quarter 2024 Results Management to Host Conference Call and Webcast August 7, 2024 at 4:30 PM ET HENDERSON, NV—August 7, 2024—P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its financial results for the second quarter ended June 30, 2024. “In
June 28, 2024	424B3	P3 Health Partners Inc. 134,768,734 Shares of Class A Common Stock Offered by the Selling Stockholders TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-280287 P3 Health Partners Inc. 134,768,734 Shares of Class A Common Stock Offered by the Selling Stockholders This prospectus relates to the proposed resale or other disposition by the Selling Stockholders (as defined herein) identified in this prospectus of up to an aggregate of 134,768,734 shares of Class A Commo
June 26, 2024	SC 13D/A	PIII / P3 Health Partners Inc. / Leavitt Equity Partners II, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2) P3 Health Partners Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 744413 105 (CUSIP Number) Taylor Leavitt Managing Partner and Chief Executive Officer Leavitt Equity Partners II, L.P. Lea
June 25, 2024	CORRESP	June 25, 2024 June 25, 2024 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.
June 18, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Exhibit 107 Calculation of Filing Fee Table Registration Statement on Form S-3 (Form Type) P3 HEALTH PARTNERS INC.
June 18, 2024	S-3	As filed with the Securities and Exchange Commission on June 18, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 18, 2024 Registration No.
June 7, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 6, 2024 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction of incorporation) (Commission Fi
May 24, 2024	EX-10.1	Securities Purchase Agreement, dated May 22, 2024, by and among P3 Health Partners Inc. and the Purchasers named therein. Exhibit 10.1 P3 HEALTH PARTNERS INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is made as of May 22, 2024 (the “Effective Date”), by and among P3 Health Partners Inc., a Delaware corporation (the “Company”), and each of those persons and entities, severally and not jointly, listed as a Purchaser on the Schedule of Purchasers attached as Exhibit A hereto (t
May 24, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 24, 2024 P3 Health Partners I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 24, 2024 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction (Commission (I.R.S. Employer of
May 24, 2024	EX-10.3	Amended and Restated Letter Agreement, dated May 24, 2024, by and among P3 Health Partners Inc., Chicago Pacific Founders GP, L.P. and Chicago Pacific Founders GP III, L.P. Exhibit 10.3 Amended and Restated LETTER AGREEMENT This AMENDED AND RESTATED LETTER AGREEMENT (this “Agreement”) is entered into as of May 24, 2024 by and among P3 Health Partners Inc., a Delaware corporation (the “Company”), Chicago Pacific Founders GP, L.P., a Delaware limited partnership (“CPF GP I”), and Chicago Pacific Founders GP III, L.P., a Delaware limited partnership (“CPF GP III”, colle
May 24, 2024	EX-10.2	Registration Rights Agreement, dated May 24, 2024, by and among P3 Health Partners Inc. and the Purchasers named therein. Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is entered into as of May 24, 2024 by and among P3 HEALTH PARTNERS INC., a Delaware corporation (the “Company”), and the sellers listed on Annex A hereto (and together with their successors and any Person that becomes a party hereto pursuant to Section 4.1, the “Sellers”). Capitalized terms that are us
May 24, 2024	EX-4.1	Form of Common Stock Purchase Warrant, dated May 24, 2024. Exhibit 4.1 THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED ‎UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND ‎HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN ‎CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR ‎DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION ‎STATEMENT RELATED THERETO OR, SUBJECT TO CERTAIN
May 24, 2024	EX-4.2	Form of Pre-Funded Common Stock Purchase Warrant, dated May 24, 2024. Exhibit 4.2 THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED ‎UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND ‎HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN ‎CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR ‎DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION ‎STATEMENT RELATED THERETO OR, SUBJECT TO CERTAIN
May 23, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 22, 2024 P3 Health Partners I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 22, 2024 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction (Commission (I.R.S. Employer of
May 20, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2024 P3 Health Partners I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2024 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction of incorporation) (Commission Fi
May 9, 2024	EX-10.4	Restricted Stock Unit Agreement under the 2024 Employment Inducement Incentive Award Plan, by and between P3 Health Partners Inc. and Aric Coffman, M.D. Exhibit 10.4 P3 HEALTH PARTNERS INC. 2024 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE P3 Health Partners Inc., a Delaware corporation (the “Company”), has granted to the participant listed below (“Participant”) the Restricted Stock Units (the “RSUs”) described in this Restricted Stock Unit Grant Notice (this “Grant Notice”), subject to the terms and conditions of
May 9, 2024	EX-10.1	Executive Employment Agreement, dated as of May 8, 2024, by and between P3 Health Partners Inc., P3 Health Group Management, LLC and Aric Coffman, M.D. Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into between P3 Health Group Management, LLC (“OpCo”), P3 Health Partners Inc., a Delaware corporation (“TopCo” and, together with OpCo, the “Company”), and Aric Coffman (the “Executive”). W I T N E S S E T H WHEREAS, the Company desires to employ the Executive as the Chief Executive Offic
May 9, 2024	EX-10.2	P3 Health Partners Inc. 2024 Employment Inducement Incentive Award Plan Exhibit 99.1 P3 HEALTH PARTNERS INC. 2024 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate Eligible Individuals who are expected to make important contributions to the Company and P3 Health Group, LLC (the “Operating Company”) by providing these individuals with equity ownership opportunities and/or
May 9, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amend UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
May 9, 2024	EX-99.1	Employment Inducement Incentive Award Plan. Exhibit 99.1 P3 HEALTH PARTNERS INC. 2024 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate Eligible Individuals who are expected to make important contributions to the Company and P3 Health Group, LLC (the “Operating Company”) by providing these individuals with equity ownership opportunities and/or
May 9, 2024	EX-99.2	2024 Employment Inducement Incentive Award Plan Form of Restricted Stock Unit Agreement. Exhibit 99.2 P3 HEALTH PARTNERS INC. 2024 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE P3 Health Partners Inc., a Delaware corporation (the “Company”), has granted to the participant listed below (“Participant”) the Restricted Stock Units (the “RSUs”) described in this Restricted Stock Unit Grant Notice (this “Grant Notice”), subject to the terms and conditions of
May 9, 2024	EX-10.5	Consulting Agreement, dated as of May 8, 2024, by and between P3 Health Partners Inc., P3 Health Group Management, LLC and Sherif Abdou, M.D. Exhibit 10.5 CONSULTING AGREEMENT This CONSULTING AGREEMENT (this “Agreement”) is entered into between P3 Health Group Management, LLC (“OpCo”), P3 Health Partners, Inc., a Delaware corporation (“TopCo” and, together with OpCo, the “Company”), and Sherif Abdou (the “Consultant”), and is effective as of the later of (i) 12:00 p.m. ET on May 8, 2024 and (ii) receipt and effectiveness of a letter fro
May 9, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107.1 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) P3 HEALTH PARTNERS INC. (Exact Name of Registrant as Specified in its Charter) Table I: Newly Registered Securities Plan Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 2024 Employment Inducemen
May 9, 2024	EX-10.3	Stock Option Agreement under the 2024 Employment Inducement Incentive Award Plan, by and between P3 Health Partners Inc. and Aric Coffman, M.D. Exhibit 10.3 P3 HEALTH PARTNERS INC. 2024 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE P3 Health Partners Inc., a Delaware corporation (the “Company”) has granted to the participant listed below (“Participant”) the stock option (the “Option”) described in this Stock Option Grant Notice (the “Grant Notice”), subject to the terms and conditions of the P3 Health Partners Inc.
May 9, 2024	S-8	As filed with the Securities and Exchange Commission on May 9, 2024 As filed with the Securities and Exchange Commission on May 9, 2024 Registration No.
May 9, 2024	EX-99.3	2024 Employment Inducement Incentive Award Plan Form of Option Agreement. Exhibit 99.3 P3 HEALTH PARTNERS INC. 2024 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE P3 Health Partners Inc., a Delaware corporation (the “Company”) has granted to the participant listed below (“Participant”) the stock option (the “Option”) described in this Stock Option Grant Notice (the “Grant Notice”), subject to the terms and conditions of the P3 Health Partners Inc.
May 9, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2024 P3 Health Partners In UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2024 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction of incorporation) (Commission Fil
May 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 8, 2024 P3 Health Partners In UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 8, 2024 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction of incorporation) (Commission Fil
May 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40033 P3 Health Partners I
May 8, 2024	EX-99.1	P3 Health Partners Announces First Quarter 2024 Results Dr. Aric Coffman joins P3 Health Partners as CEO Total revenue growth of 29% year-over-year Reaffirming 2024 guidance Anticipates reaching Adjusted EBITDA positive in 2024 Management to Host Con Exhibit 99.1 P3 Health Partners Announces First Quarter 2024 Results Dr. Aric Coffman joins P3 Health Partners as CEO Total revenue growth of 29% year-over-year Reaffirming 2024 guidance Anticipates reaching Adjusted EBITDA positive in 2024 Management to Host Conference Call and Webcast May 8, 2024 at 4:30 PM ET HENDERSON, NV—May 8, 2024—P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PII
April 26, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amend UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 26, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amend TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
March 28, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 22, 2024 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction of incorporation) (Commission
March 28, 2024	EX-10.4	Consent, by and between P3 Health Group, LLC and VBC Growth SPV LLC. Exhibit 10.4 CONSENT THIS CONSENT (this “Agreement”), dated as of March 22, 2024, is entered into among P3 HEALTH GROUP, LLC, a Delaware limited liability company (“Borrower”) and VBC Growth SPV LLC, a Delaware limited liability company (the “Holder”). All capitalized terms used herein and not otherwise defined herein shall have the meanings given to such terms in the Note (as defined below). RECI
March 28, 2024	EX-10.1	Unsecured Promissory Note, by and between P3 Health Group, LLC and VBC Growth SPV 2, LLC. Exhibit 10.1 THIS UNSECURED PROMISSORY NOTE (AS AMENDED, RESTATED OR OTHERWISE MODIFIED FROM TIME TO TIME, THIS “NOTE”) AND ANY SECURITIES WHICH MAY BE ISSUED BY THE COMPANY (AS DEFINED BELOW) UNDER ITS TERMS HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CON
March 28, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40033 P3 Health Partners Inc. (
March 28, 2024	EX-97.1	Policy for Recovery of Erroneously Awarded Compensation. Exhibit 97.1 P3 HEALTH PARTNERS INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION The Board of Directors (the “Board”) of P3 Health Partners Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of December 1, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are define
March 28, 2024	EX-99.1	P3 Health Partners Announces Fourth Quarter and Full Year 2023 Results Total revenue growth of 21% year-over-year, beating our 2023 guidance Affirming 2024 guidance Anticipates reaching Adjusted EBITDA positive in 2024 Management to Host Conference C Exhibit 99.1 P3 Health Partners Announces Fourth Quarter and Full Year 2023 Results Total revenue growth of 21% year-over-year, beating our 2023 guidance Affirming 2024 guidance Anticipates reaching Adjusted EBITDA positive in 2024 Management to Host Conference Call and Webcast March 28, 2024 at 4:30 PM ET HENDERSON, NV—March 28, 2024—P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII),
March 28, 2024	EX-21.1	List of Subsidiaries. Exhibit 21.1 Subsidiaries of the Registrant Entity Name DBA Jurisdiction of Organization P3 Health Group, LLC P3 Health Group, LLC Delaware P3 Health Group Management, LLC P3 Health Group Management, LLC Delaware P3 Health Partners, LLC P3 Health Partners, LLC Delaware P3 Health Partners-California, LLC P3 Health Partners-California, LLC Delaware P3 Health Partners-Nevada, LLC P3 Health Partners-N
March 28, 2024	EX-10.3	Fourth Amendment to Term Loan Agreement, by and among P3 Health Group, LLC, the subsidiary guarantors party thereto, the lenders party thereto and CRG Servicing LLC. Exhibit 10.3 FOURTH AMENDMENT TO TERM LOAN AGREEMENT THIS FOURTH AMENDMENT TO TERM LOAN AGREEMENT (this “Agreement”), dated as of March 22, 2024, is entered into among P3 HEALTH GROUP, LLC, a Delaware limited liability company (“Borrower”) (formerly known as FAC MERGER SUB LLC, successor by merger to P3 HEALTH GROUP HOLDINGS, LLC), the Subsidiary Guarantors party hereto, the Lenders party hereto a
March 28, 2024	EX-10.2	Subordination Agreement, by and among P3 Health Group, LLC, CRG Servicing LLC and VBC Growth SPV 2, LLC. Exhibit 10.2 SUBORDINATION AGREEMENT This Subordination Agreement (this “Agreement”) is made as of March 22, 2024 among CRG Servicing LLC, a Delaware limited liability company (“Senior Agent”), and VBC Growth SPV 2, LLC, a Delaware limited liability company (“Subordinated Creditor”). RECITALS: A. P3 Health Group, LLC, a Delaware limited liability company (“Borrower”), intends to issue in favor of
March 28, 2024	EX-10.31	Amendment No. 1 to Registration Rights Agreement and Waiver, dated November 8, 2023, by and among P3 Health Partners Inc. and certain stockholders party thereto. Exhibit 10.31 P3 HEALTH PARTNERS INC. AMENDMENT NO. 1 TO REGISTRATION RIGHTS AGREEMENT AND WAIVER November 8, 2023 This Amendment No. 1 to Registration Rights Agreement and Waiver (this “Amendment No. 1 and Waiver”) is entered into effective as of November 8, 2023 and amends that certain Registration Rights Agreement, dated as of April 6, 2023 (as amended and/or restated from time to time, the “Re
March 12, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 8, 2024 P3 Health Partners UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 8, 2024 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction of incorporation) (Commission F
March 12, 2024	EX-3.1	Amended and Restated Bylaws of the Company. Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF P3 HEALTH PARTNERS INC. (a Delaware corporation) Dated as of March 8, 2024 CONTENTS Page Article I. Meetings of Stockholders 1 Section 1.01 Place of Meetings. 1 Section 1.02 Annual Meetings. 1 Section 1.03 Special Meetings. 1 Section 1.04 Notice of Meetings. 1 Section 1.05 Adjournments. 1 Section 1.06 Quorum. 2 Section 1.07 Organization. 2 Section 1.08 Vo
March 12, 2024	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-40033 CUSIP Number: 744413105 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ T
February 27, 2024	EX-99.II	to Schedule 13G Joint Filing Agreement EX-99.II 3 d590198dex99ii.htm EX-99.II Exhibit II to Schedule 13G Joint Filing Agreement The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated February 27, 2024, in connection with their beneficial ownership of P3 Health Partners Inc. Each of, Columbia Wanger Asset Management, LLC and Columbia Management Investment Advisers, LLC authorizes Ameripr
February 27, 2024	EX-99.I	to Schedule 13G EX-99.I 2 d590198dex99i.htm EX-99.I Exhibit I to Schedule 13G Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows: Investment Adviser – Columbia Management Investment Advisers, LLC is an investment adviser registered under section 203 of the Investment Advisers Act of 1940. Investment Adviser –
February 27, 2024	SC 13G/A	PIII / P3 Health Partners Inc. / AMERIPRISE FINANCIAL INC - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment #3 Under the Securities and Exchange Act of 1934 P3 Health Partners Inc (Name of Issuer) Class A Common Stock (Title of Class of Securities) 744413105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
February 14, 2024	EX-99.II	to Schedule 13G Joint Filing Agreement EX-99.II 3 d765434dex99ii.htm EX-99.II Exhibit II to Schedule 13G Joint Filing Agreement The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated February 14, 2024, in connection with their beneficial ownership of P3 Health Partners Inc. Each of, Columbia Wanger Asset Management, LLC and Columbia Management Investment Advisers, LLC authorizes Ameripr
February 14, 2024	EX-99.I	to Schedule 13G EX-99.I 2 d765434dex99i.htm EX-99.I Exhibit I to Schedule 13G Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows: Investment Adviser – Columbia Management Investment Advisers, LLC is an investment adviser registered under section 203 of the Investment Advisers Act of 1940. Investment Adviser –
February 14, 2024	SC 13G/A	PIII / P3 Health Partners Inc. / AMERIPRISE FINANCIAL INC - SC 13G/A Passive Investment SC 13G/A 1 d765434dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment #2 Under the Securities and Exchange Act of 1934 P3 Health Partners Inc (Name of Issuer) Class A Common Stock (Title of Class of Securities) 744413105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t
February 13, 2024	SC 13G/A	PIII / P3 Health Partners Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01643-p3healthpartnersincc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: P3 Health Partners Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 744413105 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriat
February 12, 2024	SC 13G/A	PIII / P3 Health Partners Inc. / LMR Partners LLP Passive Investment SC 13G/A 1 formsc13ga-p3health.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* P3 Health Partners Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value per share (Title of Class of Securities) 744413105 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement
January 10, 2024	EX-99.1	P3 Health Partners Reaffirms Guidance for 2023 and Announces Guidance for 2024 P3 Health Partners Reaffirms Guidance for 2023 and Announces Guidance for 2024 Henderson, NV—January 9, 2024—P3 Health Partners Inc.
January 10, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 9, 2024 P3 Health Partner UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 9, 2024 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction of incorporation) (Commission
November 21, 2023	424B3	P3 Health Partners Inc. 224,444,376 Shares of Class A Common Stock 267,329 Warrants to Purchase Shares of Class A Common Stock 10,819,105 Shares of Class A Common Stock underlying Warrants TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-261904 P3 Health Partners Inc. 224,444,376 Shares of Class A Common Stock 267,329 Warrants to Purchase Shares of Class A Common Stock 10,819,105 Shares of Class A Common Stock underlying Warrants This prospectus relates to (i) the resale of 8,655,131 shares (the “PIPE Shares”) of Class A Common Stock, par value $0.0001 per s
November 21, 2023	424B3	P3 Health Partners Inc. 136,685,830 Shares of Class A Common Stock Offered by the Selling Stockholders TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-271565 P3 Health Partners Inc. 136,685,830 Shares of Class A Common Stock Offered by the Selling Stockholders This prospectus relates to the proposed resale or other disposition by the Selling Stockholders (as defined herein) identified in this prospectus of up to an aggregate of 136,685,830 shares of Class A Common Stock, p
November 16, 2023	CORRESP	November 16, 2023 November 16, 2023 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
November 14, 2023	424B3	P3 Health Partners, Inc. 139,847,114 Shares of Class A Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-271565 Prospectus Supplement No. 4 (To Prospectus dated June 14, 2023) P3 Health Partners, Inc. 139,847,114 Shares of Class A Common Stock This prospectus supplement updates, amends and supplements the prospectus dated June 14, 2023 (the “Prospectus”), relating to the resale or other disposition by the selling stockholders identified in the pro
November 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 8, 2023 P3 Health Partne UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 8, 2023 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction of incorporation) (Commissio
November 14, 2023	424B3	P3 Health Partners, Inc. 231,277,198 Shares of Class A Common Stock 267,329 Warrants to Purchase Shares of Class A Common Stock 10,819,105 Shares of Class A Common Stock underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-261904 Prospectus Supplement No. 4 (To Prospectus dated June 14, 2023) P3 Health Partners, Inc. 231,277,198 Shares of Class A Common Stock 267,329 Warrants to Purchase Shares of Class A Common Stock 10,819,105 Shares of Class A Common Stock underlying Warrants This prospectus supplement updates, amends and supplements the prospectus dated June
November 9, 2023	EX-4.3	Form of Indenture. Exhibit 4.3 P3 HEALTH PARTNERS INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Establish
November 9, 2023	POS AM	As filed with the Securities and Exchange Commission on November 9, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 9, 2023 Registration No.
November 9, 2023	EX-99.1	REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 99.1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Stockholders and Board of Directors of P3 Health Partners Inc. (f/k/a Foresight Acquisition Corp.) Opinion on the Financial Statements We have audited the accompanying consolidated balance sheet of P3 Health Partners Inc. (f/k/a Foresight Acquisition Corp.) (the “Company”) as of December 2, 2021 and December 31, 2020, the
November 9, 2023	S-3	As filed with the Securities and Exchange Commission on November 9, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 9, 2023 Registration No.
November 9, 2023	EX-1.2	, dated as of November 9, 2023, by and between P3 Health Partners Inc. and Jefferies LLC. Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM November 9, 2023 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: P3 Health Partners Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s Class
November 9, 2023	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 9, 2023 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction of incorporation) (Commissio
November 9, 2023	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) P3 Health Partners Inc.
November 9, 2023	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) P3 HEALTH PARTNERS INC.
November 9, 2023	POS AM	As filed with the Securities and Exchange Commission on November 9, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 9, 2023 Registration No.
November 8, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40033 P3 Health Partne
November 8, 2023	EX-10.2	Transaction Bonus Restricted Stock Unit Agreement by and between Amir Bacchus, M.D. and P3 Health Partners Inc., dated August 4, 2023. Exhibit 10.2 P3 HEALTH PARTNERS INC. 2021 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE P3 Health Partners Inc., a Delaware corporation (the “Company”), has granted to the participant listed below (“Participant”) the Restricted Stock Units (the “RSUs”) described in this Restricted Stock Unit Grant Notice (this “Grant Notice”), subject to the terms and conditions of the P3 Health Partners
November 8, 2023	EX-10.1	Transaction Bonus Restricted Stock Unit Agreement by and between Sherif Abdou, M.D. and P3 Health Partners Inc., dated August 4, 2023. Exhibit 10.1 P3 HEALTH PARTNERS INC. 2021 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE P3 Health Partners Inc., a Delaware corporation (the “Company”), has granted to the participant listed below (“Participant”) the Restricted Stock Units (the “RSUs”) described in this Restricted Stock Unit Grant Notice (this “Grant Notice”), subject to the terms and conditions of the P3 Health Partners
November 8, 2023	EX-99.1	P3 Health Partners Announces Third-Quarter and Year-to-Date 2023 Results YTD total revenue growth of 16% Continued strong performance across markets, re-affirming 2023 guidance Provides preliminary 2024 Full-Year Adjusted EBITDA guidance of +$20 mill P3 Health Partners Announces Third-Quarter and Year-to-Date 2023 Results YTD total revenue growth of 16% Continued strong performance across markets, re-affirming 2023 guidance Provides preliminary 2024 Full-Year Adjusted EBITDA guidance of +$20 million to +$40 million Management to Host Conference Call and Webcast November 8, 2023 at 4:30 PM ET HENDERSON, NV—November 8, 2023—P3 Health Partners Inc.
November 8, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 8, 2023 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction of incorporation) (Commissio
November 8, 2023	424B3	P3 Health Partners, Inc. 231,277,198 Shares of Class A Common Stock 267,329 Warrants to Purchase Shares of Class A Common Stock 10,819,105 Shares of Class A Common Stock underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-261904 Prospectus Supplement No. 3 (To Prospectus dated June 14, 2023) P3 Health Partners, Inc. 231,277,198 Shares of Class A Common Stock 267,329 Warrants to Purchase Shares of Class A Common Stock 10,819,105 Shares of Class A Common Stock underlying Warrants This prospectus supplement updates, amends and supplements the prospectus dated June
November 8, 2023	424B3	P3 Health Partners, Inc. 139,847,114 Shares of Class A Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-271565 Prospectus Supplement No. 3 (To Prospectus dated June 14, 2023) P3 Health Partners, Inc. 139,847,114 Shares of Class A Common Stock This prospectus supplement updates, amends and supplements the prospectus dated June 14, 2023 (the “Prospectus”), relating to the resale or other disposition by the selling stockholders identified in the pro
November 3, 2023	SC 13D/A	PIII / P3 Health Partners Inc - Class A / Abdou Sherif - SC 13D/A Activist Investment SC 13D/A 1 drsherifabdousc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* P3 Health Partners Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 744413 105 (CUSIP Number) Sherif Abdou, M.D. c/o P3 Health Partners Inc. 2370 Corporate Circle, Suite 300 Henderson,
August 7, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40033 P3 Health Partners In
August 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 7, 2023 P3 Health Partners UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 7, 2023 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction of incorporation) (Commission
August 7, 2023	EX-99.1	P3 Health Partners Announces Second-Quarter 2023 Results Management to Host Conference Call and Webcast August 7, 2023 at 4:30 PM ET P3 Health Partners Announces Second-Quarter 2023 Results Management to Host Conference Call and Webcast August 7, 2023 at 4:30 PM ET HENDERSON, NV—August 7, 2023—P3 Health Partners Inc.
August 7, 2023	424B3	P3 Health Partners, Inc. 231,277,198 Shares of Class A Common Stock 267,329 Warrants to Purchase Shares of Class A Common Stock 10,819,105 Shares of Class A Common Stock underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-261904 Prospectus Supplement No. 2 (To Prospectus dated June 14, 2023) P3 Health Partners, Inc. 231,277,198 Shares of Class A Common Stock 267,329 Warrants to Purchase Shares of Class A Common Stock 10,819,105 Shares of Class A Common Stock underlying Warrants This prospectus supplement updates, amends and supplements the prospectus dated June
August 7, 2023	424B3	P3 Health Partners, Inc. 139,847,114 Shares of Class A Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-271565 Prospectus Supplement No. 2 (To Prospectus dated June 14, 2023) P3 Health Partners, Inc. 139,847,114 Shares of Class A Common Stock This prospectus supplement updates, amends and supplements the prospectus dated June 14, 2023 (the “Prospectus”), relating to the resale or other disposition by the selling stockholders identified in the pro
July 27, 2023	424B3	P3 Health Partners, Inc. 139,847,114 Shares of Class A Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-271565 Prospectus Supplement No. 1 (To Prospectus dated June 14, 2023) P3 Health Partners, Inc. 139,847,114 Shares of Class A Common Stock This prospectus supplement updates, amends and supplements the prospectus dated June 14, 2023 (the “Prospectus”), relating to the resale or other disposition by the selling stockholders identified in the pro
July 27, 2023	424B3	P3 Health Partners, Inc. 231,277,198 Shares of Class A Common Stock 267,329 Warrants to Purchase Shares of Class A Common Stock 10,819,105 Shares of Class A Common Stock underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-261904 Prospectus Supplement No. 1 (To Prospectus dated June 14, 2023) P3 Health Partners, Inc. 231,277,198 Shares of Class A Common Stock 267,329 Warrants to Purchase Shares of Class A Common Stock 10,819,105 Shares of Class A Common Stock underlying Warrants This prospectus supplement updates, amends and supplements the prospectus dated June
July 26, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 24, 2023 P3 Health Partners UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 24, 2023 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction of incorporation) (Commission F
June 15, 2023	424B3	P3 Health Partners Inc. 139,847,114 Shares of Class A Common Stock Offered by the Selling Stockholders TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-271565 P3 Health Partners Inc. 139,847,114 Shares of Class A Common Stock Offered by the Selling Stockholders This prospectus relates to the proposed resale or other disposition by the Selling Stockholders (as defined herein) identified in this prospectus of up to an aggregate of 139,847,114 shares of Class A Common Stock, p
June 15, 2023	424B3	P3 Health Partners Inc. 231,277,198 Shares of Class A Common Stock 267,329 Warrants to Purchase Shares of Class A Common Stock 10,819,105 Shares of Class A Common Stock underlying Warrants TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-261904 P3 Health Partners Inc. 231,277,198 Shares of Class A Common Stock 267,329 Warrants to Purchase Shares of Class A Common Stock 10,819,105 Shares of Class A Common Stock underlying Warrants This prospectus relates to (i) the resale of 14,843,424 shares (the “PIPE Shares”) of Class A Common Stock, par value $0.0001 per
June 12, 2023	CORRESP	June 12, 2023 June 12, 2023 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
June 8, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amend TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
June 8, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amend UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
May 17, 2023	S-1/A	As filed with the Securities and Exchange Commission on May 17, 2023 Table of Contents As filed with the Securities and Exchange Commission on May 17, 2023 Registration No.
May 17, 2023	POS AM	As filed with the Securities and Exchange Commission on May 17, 2023 Table of Contents As filed with the Securities and Exchange Commission on May 17, 2023 Registration No.
May 11, 2023	424B3	P3 Health Partners, Inc. 240,855,865 Shares of Class A Common Stock 267,329 Warrants to Purchase Shares of Class A Common Stock 10,819,105 Shares of Class A Common Stock underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-261904 Prospectus Supplement No. 10 (To Prospectus dated November 10, 2022) P3 Health Partners, Inc. 240,855,865 Shares of Class A Common Stock 267,329 Warrants to Purchase Shares of Class A Common Stock 10,819,105 Shares of Class A Common Stock underlying Warrants This prospectus supplement updates, amends and supplements the prospectus dated
May 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 10, 2023 P3 Health Partners I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 10, 2023 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction of incorporation) (Commission Fi
May 10, 2023	EX-99.1	P3 Health Partners Announces First-Quarter 2023 Results –Capitated revenue increases 11% vs. the same period in the prior year –Q1 2023 operating loss improved 7% vs. the same period in the prior year –Q1 2023 medical margin improvement of 58% vs. th P3 Health Partners Announces First-Quarter 2023 Results –Capitated revenue increases 11% vs.
May 10, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40033 P3 Health Partners I
May 2, 2023	EX-FILING FEES	Filing Fee Table (previously filed as Exhibit 107 to the Company’s Form S-1 (333-271565), filed with the SEC on May 2, 2023). EX-FILING FEES 5 piii-20221231xexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Registration Statement on Form S-1 (Form Type) P3 HEALTH PARTNERS INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offe
May 2, 2023	POS AM	As filed with the Securities and Exchange Commission on May 1, 2023 Table of Contents As filed with the Securities and Exchange Commission on May 1, 2023 Registration No.
May 2, 2023	S-1	As filed with the Securities and Exchange Commission on May 1, 2023 Table of Contents As filed with the Securities and Exchange Commission on May 1, 2023 Registration No.
May 1, 2023	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 1 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40033 P3 Heal
April 25, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 25, 2023 P3 Health Partners UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 25, 2023 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction (Commission (I.R.S. Employer o
April 25, 2023	424B3	P3 Health Partners, Inc. 240,855,865 Shares of Class A Common Stock 267,329 Warrants to Purchase Shares of Class A Common Stock 10,819,105 Shares of Class A Common Stock underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-261904 Prospectus Supplement No. 9 (To Prospectus dated November 10, 2022) P3 Health Partners, Inc. 240,855,865 Shares of Class A Common Stock 267,329 Warrants to Purchase Shares of Class A Common Stock 10,819,105 Shares of Class A Common Stock underlying Warrants This prospectus supplement updates, amends and supplements the prospectus dated N
April 21, 2023	EX-99.5	LETTER AGREEMENT EX-99.5 Exhibit 99.5 LETTER AGREEMENT This LETTER AGREEMENT (this “Agreement”) is entered into as of April 6, 2023 by and among P3 Health Partners Inc., a Delaware corporation (the “Company”), Chicago Pacific Founders GP, L.P., a Delaware limited partnership (“CPF GP I”), and Chicago Pacific Founders GP III, L.P., a Delaware limited partnership (“CPF GP III”, collectively with CPF GP I, “CPF”) (in
April 21, 2023	EX-99.3	P3 HEALTH PARTNERS INC. SECURITIES PURCHASE AGREEMENT EX-99.3 Exhibit 99.3 P3 HEALTH PARTNERS INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is made as of March 30, 2023 (the “Effective Date”), by and among P3 Health Partners Inc., a Delaware corporation (the “Company”), and each of those persons and entities, severally and not jointly, listed as a Purchaser on the Schedule of Purchasers attached as Exhibit A
April 21, 2023	SC 13D/A	PIII / P3 Health Partners Inc - Class A / Chicago Pacific Founders UGP, LLC - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT No. 2 to SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) P3 Health Partners Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 744413 105 (CUSIP Number) Michael J. Wilson Chief Financial Officer and Chief Compliance Officer Chicago
April 21, 2023	EX-99.4	REGISTRATION RIGHTS AGREEMENT EX-99.4 Exhibit 99.4 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is entered into as of April 6, 2023 by and among P3 HEALTH PARTNERS INC., a Delaware corporation (the “Company”), and the sellers listed on Annex A hereto (and together with their successors and any Person that becomes a party hereto pursuant to Section 4.1, the “Sellers”). Capitalized terms th
April 21, 2023	EX-99.2	P3 HEALTH PARTNERS INC. Pre-Funded Warrant EX-99.2 Exhibit 99.2 THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO CER
April 21, 2023	EX-99.1	P3 HEALTH PARTNERS INC. Class A Common Stock Purchase Warrant EX-99.1 Exhibit 99.1 THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO CER
April 19, 2023	SC 13D/A	PIII / P3 Health Partners Inc - Class A / Leavitt Equity Partners II, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) P3 Health Partners Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 744413 105 (CUSIP Number) Taylor Leavitt Managing Partner and Chief Executive Officer Leavitt Equity Partners II, L.P. Leavi
April 19, 2023	EX-11	JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-11 Exhibit 11 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) This joint filing agreement is made pursuant to Rule 13d-l(k)(1) under the Securities and Exchange Act of 1934, as amended (the “Act”), by and among the parties listed below, each referenced to herein as a “Joint Filer”.
April 14, 2023	SC 13D/A	PIII / P3 Health Partners Inc - Class A / Bacchus Amir - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* P3 Health Partners Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 744413105 (CUSIP Number) Amir Bacchus, M.D. c/o P3 Health Partners Inc. 2370 Corporate Circle, Suite 300 Henderson, NV 89074 (702) 910-3950 (Name, Address and Te
April 10, 2023	AW	April 10, 2023 April 10, 2023 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
April 10, 2023	POS EX	As filed with the Securities and Exchange Commission on April 10, 2023 As filed with the Securities and Exchange Commission on April 10, 2023 Registration No.
April 7, 2023	EX-4.1	Form of Common Stock Purchase Warrant, dated April 6, 2023. Exhibit 4.1 THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED ‎UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND ‎HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN ‎CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR ‎DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION ‎STATEMENT RELATED THERETO OR, SUBJECT TO CERTAIN
April 7, 2023	EX-4.2	Form of Pre-Funded Common Stock Purchase Warrant, dated April 6, 2023. Exhibit 4.2 THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED ‎UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND ‎HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN ‎CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR ‎DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION ‎STATEMENT RELATED THERETO OR, SUBJECT TO CERTAIN
April 7, 2023	EX-10.3	Letter Agreement, dated April 6, 2023, by and among P3 Health Partners Inc., Chicago Pacific Founders GP, L.P. and Chicago Pacific Founders GP III, L.P.  Exhibit 10.3   LETTER AGREEMENT   This LETTER AGREEMENT (this “Agreement”) is entered into as of April 6, 2023 by and among P3 Health Partners Inc., a Delaware corporation (the “Company”), Chicago Pacific Founders GP, L.P., a Delaware limited partnership (“CPF GP I”), and Chicago Pacific Founders GP III, L.P., a Delaware limited partnership (“CPF GP III”, collectively with CPF GP I, “CPF”) (in th
April 7, 2023	EX-10.2	Registration Rights Agreement, dated April 6, 2023, by and among P3 Health Partners Inc. and the Purchasers named therein. Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT   This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is entered into as of April 6, 2023 by and among P3 HEALTH PARTNERS INC., a Delaware corporation (the “Company”), and the sellers listed on Annex A hereto (and together with their successors and any Person that becomes a party hereto pursuant to Section 4.1, the “Sellers”). Capitalized terms that are
April 7, 2023	EX-10.1	Securities Purchase Agreement, dated March 30, 2023, by and among P3 Health Partners Inc. and the Purchasers named therein. Exhibit 10.1 P3 HEALTH PARTNERS INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is made as of March 30, 2023 (the “Effective Date”), by and among P3 Health Partners Inc., a Delaware corporation (the “Company”), and each of those persons and entities, severally and not jointly, listed as a Purchaser on the Schedule of Purchasers attached as Exhibit A hereto
April 7, 2023	EX-10.2	Registration Rights Agreement, dated April 6, 2023, by and among P3 Health Partners Inc. and the Purchasers named therein. Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT   This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is entered into as of April 6, 2023 by and among P3 HEALTH PARTNERS INC., a Delaware corporation (the “Company”), and the sellers listed on Annex A hereto (and together with their successors and any Person that becomes a party hereto pursuant to Section 4.1, the “Sellers”). Capitalized terms that are
April 7, 2023	EX-10.1	Securities Purchase Agreement, dated March 30, 2023, by and among P3 Health Partners Inc. and the Purchasers named therein. Exhibit 10.1 P3 HEALTH PARTNERS INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is made as of March 30, 2023 (the “Effective Date”), by and among P3 Health Partners Inc., a Delaware corporation (the “Company”), and each of those persons and entities, severally and not jointly, listed as a Purchaser on the Schedule of Purchasers attached as Exhibit A hereto
April 7, 2023	EX-10.3	Letter Agreement, dated April 6, 2023, by and among P3 Health Partners Inc., Chicago Pacific Founders GP, L.P. and Chicago Pacific Founders GP III, L.P.  Exhibit 10.3   LETTER AGREEMENT   This LETTER AGREEMENT (this “Agreement”) is entered into as of April 6, 2023 by and among P3 Health Partners Inc., a Delaware corporation (the “Company”), Chicago Pacific Founders GP, L.P., a Delaware limited partnership (“CPF GP I”), and Chicago Pacific Founders GP III, L.P., a Delaware limited partnership (“CPF GP III”, collectively with CPF GP I, “CPF”) (in th
April 7, 2023	424B3	P3 Health Partners, Inc. 240,855,865 Shares of Class A Common Stock 267,329 Warrants to Purchase Shares of Class A Common Stock 10,819,105 Shares of Class A Common Stock underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-261904 Prospectus Supplement No. 8 (To Prospectus dated November 10, 2022) P3 Health Partners, Inc. 240,855,865 Shares of Class A Common Stock 267,329 Warrants to Purchase Shares of Class A Common Stock 10,819,105 Shares of Class A Common Stock underlying Warrants This prospectus supplement updates, amends and supplements the prospectus dated N
April 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 6, 2023 P3 Health Partners UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 6, 2023 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction (Commission (I.R.S. Employer of
April 7, 2023	EX-4.1	Form of Common Stock Purchase Warrant, dated April 6, 2023. Exhibit 4.1 THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED ‎UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND ‎HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN ‎CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR ‎DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION ‎STATEMENT RELATED THERETO OR, SUBJECT TO CERTAIN
April 7, 2023	EX-4.2	Form of Pre-Funded Common Stock Purchase Warrant, dated April 6, 2023. Exhibit 4.2 THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED ‎UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND ‎HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN ‎CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR ‎DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION ‎STATEMENT RELATED THERETO OR, SUBJECT TO CERTAIN
March 31, 2023	EX-21.1	List of Subsidiaries. Exhibit 21.1 Subsidiaries of the Registrant Entity Name DBA Jurisdiction of Organization P3 Health Group, LLC P3 Health Group, LLC Delaware P3 Health Partners, LLC P3 Health Partners, LLC Delaware P3 Health Partners-California, LLC P3 Health Partners-California, LLC Delaware P3 Health Partners-Nevada, LLC P3 Health Partners-Nevada, LLC Delaware P3 Health Partners-Oregon LLC P3 Health Partners-Oreg
March 31, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 31, 2023 P3 Health Partners UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 31, 2023 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction (Commission (I.R.S. Employer o
March 31, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40033 P3 Heal
March 31, 2023	424B3	P3 Health Partners, Inc. 240,855,865 Shares of Class A Common Stock 267,329 Warrants to Purchase Shares of Class A Common Stock 10,819,105 Shares of Class A Common Stock underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-261904 Prospectus Supplement No. 6 (To Prospectus dated November 10, 2022) P3 Health Partners, Inc. 240,855,865 Shares of Class A Common Stock 267,329 Warrants to Purchase Shares of Class A Common Stock 10,819,105 Shares of Class A Common Stock underlying Warrants This prospectus supplement updates, amends and supplements the prospectus dated N
March 31, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 30, 2023 P3 Health Partners UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 30, 2023 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction (Commission (I.R.S. Employer o
March 31, 2023	424B3	P3 Health Partners, Inc. 240,855,865 Shares of Class A Common Stock 267,329 Warrants to Purchase Shares of Class A Common Stock 10,819,105 Shares of Class A Common Stock underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-261904 Prospectus Supplement No. 7 (To Prospectus dated November 10, 2022) P3 Health Partners, Inc. 240,855,865 Shares of Class A Common Stock 267,329 Warrants to Purchase Shares of Class A Common Stock 10,819,105 Shares of Class A Common Stock underlying Warrants This prospectus supplement updates, amends and supplements the prospectus dated N
March 31, 2023	EX-99.1	P3 Health Partners Announces Fourth Quarter and Full-Year 2022 Results Affirming 2023 guidance – introducing year-end medical margin guidance Anticipates reaching Adjusted EBITDA positive in early 2024 Management to Host Conference Call and Webcast M Exhibit 99.1 P3 Health Partners Announces Fourth Quarter and Full-Year 2022 Results Affirming 2023 guidance – introducing year-end medical margin guidance Anticipates reaching Adjusted EBITDA positive in early 2024 Management to Host Conference Call and Webcast March 31, 2023 at 8:30 AM ET Henderson, NV, March 31, 2023 (Business Wire) - P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII
March 31, 2023	POS AM	As filed with the Securities and Exchange Commission on March 31, 2023 As filed with the Securities and Exchange Commission on March 31, 2023 Registration No.
March 17, 2023	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-40033 CUSIP Number: 744413105 (Check one): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31, 2022 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ T
March 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 14, 2023 P3 Health Partners UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 14, 2023 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction (Commission (I.R.S. Employer o
March 15, 2023	EX-99.1	P3 Health Partners Affirms 2023 Outlook Schedules Earnings Call for 2022 Results Exhibit 99.1 P3 Health Partners Affirms 2023 Outlook and Schedules Earnings Call for 2022 Results Henderson, Nev., March 14, 2023, (Business Wire) - P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that it expects to file the Company’s Annual Report on Form 10-K on or before the close of busin
February 14, 2023	EX-99.II	to Schedule 13G Joint Filing Agreement EX-99.II 3 d403871dex99ii.htm EX-99.II Exhibit II to Schedule 13G Joint Filing Agreement The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated February 14, 2023 in connection with their beneficial ownership of P3 Health Partners Inc. Each of Columbia Acorn Fund, Columbia Wanger Asset Management, LLC and Columbia Management Investment Advisers, LLC
February 14, 2023	EX-99.I	to Schedule 13G EX-99.I 2 d403871dex99i.htm EX-99.I Exhibit I to Schedule 13G Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows: Investment Adviser – Columbia Management Investment Advisers, LLC is an investment adviser registered under section 203 of the Investment Advisers Act of 1940. Investment Adviser –
February 14, 2023	SC 13G/A	PIII / P3 Health Partners Inc - Class A / AMERIPRISE FINANCIAL INC - SC 13G/A Passive Investment SC 13G/A 1 d403871dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment #1 Under the Securities and Exchange Act of 1934 P3 Health Partners Inc (Name of Issuer) Class A Common Stock (Title of Class of Securities) 744413105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t
February 14, 2023	SC 13G/A	PIII / P3 Health Partners Inc - Class A / LMR Partners LLP - SC 13G/A Passive Investment SC 13G/A 1 d466828dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* P3 Health Partners Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value per share (Title of Class of Securities) 744413105 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this state
February 14, 2023	EX-99.1	JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersig
February 9, 2023	SC 13G/A	PIII / P3 Health Partners Inc - Class A / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: P3 Health Partners Inc. Title of Class of Securities: Common Stock CUSIP Number: 744413105 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is file
January 25, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 19, 2023 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction (Commission (I.R.S. Employer
January 25, 2023	424B3	P3 Health Partners, Inc. 240,855,865 Shares of Class A Common Stock 267,329 Warrants to Purchase Shares of Class A Common Stock 10,819,105 Shares of Class A Common Stock underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-261904 Prospectus Supplement No. 5 (To Prospectus dated November 10, 2022) P3 Health Partners, Inc. 240,855,865 Shares of Class A Common Stock 267,329 Warrants to Purchase Shares of Class A Common Stock 10,819,105 Shares of Class A Common Stock underlying Warrants This prospectus supplement updates, amends and supplements the prospectus dated N
January 11, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 11, 2023 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction (Commission (I.R.S. Employer
January 11, 2023	EX-99.1	P3 Health Partners Reaffirms Guidance For 2022 and Announces Guidance For 2023 Exhibit 99.1 P3 Health Partners Reaffirms Guidance For 2022 and Announces Guidance For 2023 Henderson, Nev., January 11, 2023 - P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, is participating in J.P. Morgan’s 41st Annual Healthcare Conference, being held in San Francisco, CA from January 9-12, 2023. In adva
December 28, 2022	SC 13D/A	PIII / P3 Health Partners Inc - Class A / Bacchus Amir - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* P3 Health Partners Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 744413 105 (CUSIP Number) Amir Bacchus, M.D. c/o P3 Health Partners Inc. 2370 Corporate Circle, Suite 300 Henderson, NV 89074 (702) 910-3950 (Name, Addr
December 23, 2022	SC 13D/A	PIII / P3 Health Partners Inc - Class A / Chicago Pacific Founders UGP, LLC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT No. 1 to SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) P3 Health Partners Inc. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 744413 105 (CUSIP Number) Michael J. Wilson Chief Financial Officer and Chief Compliance Officer Chicago Pacific Fo
December 23, 2022	EX-99.1	VBC GROWTH SPV, LLC LIMITED LIABILITY COMPANY AGREEMENT Exhibit 99.1 Execution Version VBC GROWTH SPV, LLC LIMITED LIABILITY COMPANY AGREEMENT THIS LIMITED LIABILITY COMPANY AGREEMENT (this ?Agreement?) of VBC Growth SPV, LLC (the ?Company?), is entered into as of December 13, 2022 (the ?Effective Date?) by and among the Members (as defined below). WHEREAS, the Members have formed the Company for the limited purpose of providing financing to and holdin
December 21, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 16, 2022 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction (Commission (I.R.S. Employe
December 21, 2022	424B3	P3 Health Partners, Inc. 240,855,865 Shares of Class A Common Stock 267,329 Warrants to Purchase Shares of Class A Common Stock 10,819,105 Shares of Class A Common Stock underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-261904 Prospectus Supplement No. 4 (To Prospectus dated November 10, 2022) P3 Health Partners, Inc. 240,855,865 Shares of Class A Common Stock 267,329 Warrants to Purchase Shares of Class A Common Stock 10,819,105 Shares of Class A Common Stock underlying Warrants This prospectus supplement updates, amends and supplements the prospectus dated N
December 13, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 13, 2022 P3 Health Partn UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 13, 2022 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction (Commission (I.R.S. Employe
December 13, 2022	EX-10.4	Third Amendment to Term Loan Agreement, dated as of December 13, 2022, by and among P3 Health Group, LLC, as borrower, the Subsidiary Guarantors party thereto, the Lenders party thereto and CRG Servicing LLC, as administrative agent and collateral agent. Exhibit 10.4 THIRD AMENDMENT TO TERM LOAN AGREEMENT THIS THIRD AMENDMENT TO TERM LOAN AGREEMENT (this “Agreement”), dated as of December 13, 2022, is entered into among P3 HEALTH GROUP, LLC, a Delaware limited liability company (“Borrower”) (formerly known as FAC MERGER SUB LLC, successor by merger to P3 HEALTH GROUP HOLDINGS, LLC), the Subsidiary Guarantors party hereto, the Lenders party hereto
December 13, 2022	EX-10.1	Unsecured Promissory Note, dated December 13, 2022, by and between P3 Health Partners LLC and VBC Growth SPV LLC (incorporated by reference to Exhibit 10.1 to the registrant’s Current Report on Form 8-K filed on December 13, 2022). Exhibit 10.1 THIS Unsecured Promissory Note (AS AMENDED, RESTATED OR OTHERWISE MODIFIED FROM TIME TO TIME, this “NOTE”) AND ANY SECURITIES WHICH MAY BE ISSUED BY THE COMPANY (AS DEFINED BELOW) UNDER ITS TERMS HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CON
December 13, 2022	424B3	P3 Health Partners, Inc. 240,855,865 Shares of Class A Common Stock 267,329 Warrants to Purchase Shares of Class A Common Stock 10,819,105 Shares of Class A Common Stock underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-261904 Prospectus Supplement No. 3 (To Prospectus dated November 10, 2022) P3 Health Partners, Inc. 240,855,865 Shares of Class A Common Stock 267,329 Warrants to Purchase Shares of Class A Common Stock 10,819,105 Shares of Class A Common Stock underlying Warrants This prospectus supplement updates, amends and supplements the prospectus dated N
December 13, 2022	EX-10.3	Subordination Agreement, dated as of December 13, 2022, by and among CRG Servicing, LLC and VBC Growth SPV LLC (incorporated by reference to Exhibit 10.3 to the registrant’s Current Report on Form 8-K filed on December 13, 2022). Exhibit 10.3 SUBORDINATION AGREEMENT This Subordination Agreement (this “Agreement”) is made as of December 13, 2022 among CRG Servicing LLC, a Delaware limited liability company (“Senior Agent”), and VBC Growth SPV LLC, a Delaware limited liability company (“Subordinated Creditor”). RECITALS: A. P3 Health Group, LLC, a Delaware limited liability company (“Borrower”), intends to issue in favor of
December 13, 2022	EX-10.2	Warrant Agreement, dated December 13, 2022, by and between P3 Health Partners LLC and VBC Growth SPC LLC (incorporated by reference to Exhibit 10.2 to the registrant’s Current Report on Form 8-K filed on February 13, 2022). Exhibit 10.2 THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO CERTAIN EXC
December 5, 2022	424B3	P3 Health Partners, Inc. 240,855,865 Shares of Class A Common Stock 267,329 Warrants to Purchase Shares of Class A Common Stock 10,819,105 Shares of Class A Common Stock underlying Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-261904 Prospectus Supplement No. 2 (To Prospectus dated November 10, 2022) P3 Health Partners, Inc. 240,855,865 Shares of Class A Common Stock 267,329 Warrants to Purchase Shares of Class A Common Stock 10,819,105 Shares of Class A Common Stock underlying Warrants This prospectus supplement updates, amends and supplements the prospectus dated N
December 1, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 27, 2022 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction (Commission (I.R.S. Employe
December 1, 2022	EX-10.2	Letter Agreement, dated as of November 27, 2022, by and between P3 Health Group Holdings, LLC and Atul Kavthekar (incorporated by reference to Exhibit 10.2 to the registrant’s Current Report on Form 8-K filed on December 1, 2022). Exhibit 10.2 November 27, 2022 Atul Kavthekar 3407 Fairmont Avenue Naperville, IL 60564 Via email: [email protected] Dear Atul, We are pleased to extend to you an offer of employment as Chief Financial Officer of P3 Health Partners. We believe that all employees contribute directly to the Company?s growth and success, and we look forward to you being a member of our team. Following are the t
December 1, 2022	EX-10.1	Letter Agreement, by and between P3 Health Partners Inc. and Erin Darakjian Exhibit 10.1 November 28, 2022 Erin Darakjian Chief Accounting Officer Interim Chief Financial Officer Dear Erin, We are pleased to extend an interim pay agreement for your work as P3?s Interim CFO and in your continued role as Chief Accounting Officer. You are a trusted and highly valued leader of our P3 family, and your contributions are directly connected to the company?s growth and success. Th
November 14, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 14, 2022 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction (Commission (I.R.S. Employe
November 14, 2022	424B3	P3 Health Partners, Inc. 240,855,865 Shares of Class A Common Stock 267,329 Warrants to Purchase Shares of Class A Common Stock 10,819,105 Shares of Class A Common Stock underlying Warrants Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-261904 Prospectus Supplement No. 1 (To Prospectus dated November 10, 2022) P3 Health Partners, Inc. 240,855,865 Shares of Class A Common Stock 267,329 Warrants to Purchase Shares of Class A Common Stock 10,819,105 Shares of Class A Common Stock underlying Warrants This prospectus supplement updates, amends and supplements the
November 14, 2022	10-Q	z UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents z ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
November 14, 2022	424B3	P3 Health Partners Inc. 240,855,865 Shares of Class A Common Stock 267,329 Warrants to Purchase Shares of Class A Common Stock 10,819,105 Shares of Class A Common Stock underlying Warrants TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(3) ?Registration No. 333-261904? P3 Health Partners Inc. 240,855,865 Shares of Class A Common Stock 267,329 Warrants to Purchase Shares of Class A Common Stock 10,819,105 Shares of Class A Common Stock underlying Warrants ? This prospectus relates to (i) the resale of 19,993,207 shares (the ?PIPE Shares?) of Class A Common Stock, par value $0.0001 p
November 14, 2022	EX-99.1	P3 Health Partners Provides Third-Quarter and Year-to-Date 2022 Financial Results Exhibit 99.1 P3 Health Partners Provides Third-Quarter and Year-to-Date 2022 Financial Results ? Strong Third-Quarter YTD 2022 revenue growth of 59% compared to the Third-Quarter YTD 2021 ? At-risk Medicare Advantage members exceeded 101,000 at the end of the Third Quarter of 2022 ? Third-Quarter YTD 2022 Net loss PMPM increased to $1,132 from $159 for Third-quarter YTD 2021, primarily due to an $
November 14, 2022	EX-10.1	Separation Agreement, effective as of November 1, 2022, by and between P3 Health Partners Inc. and Eric Atkins (incorporated by reference to Exhibit 10.1 to the registrant’s Quarterly Report on Form 10-Q filed on November 14, 2022). ? Exhibit 10.1 CONFIDENTIAL SEPARATION AGREEMENT AND RELEASE This Confidential Separation Agreement and Release (the ?Agreement?) is entered into by and between Eric Atkins (?Employee?), P3 Health Partners Inc. (the ?Company?), P3 Health Group Management, LLC (?Employer?), and P3 Health Group, LLC (?P3 LLC?) (each individually referred to as a ?Party? and collectively as ?Parties?). Employee resig
November 7, 2022	POS AM	As filed with the Securities and Exchange Commission on November 7, 2022 Table of Contents As filed with the Securities and Exchange Commission on November 7, 2022 Registration No.
November 3, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amend DEFA14A 1 ny20005313x2defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box
November 3, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amend TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
October 27, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 24, 2022 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction (Commission (I.R.S. Employer
October 21, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
October 21, 2022	EX-FILING FEES	Ex Filing Fees. EXHIBIT 107 Calculation of Filing Fee Tables S-8 (Form Type) P3 HEALTH PARTNERS INC.
October 21, 2022	S-8	As filed with the Securities and Exchange Commission on October 21, 2022 As filed with the Securities and Exchange Commission on October 21, 2022 Registration No.
October 21, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
October 21, 2022	EX-10.19	First Amendment to Repurchase Promissory Note between P3 Health Group Holdings, LLC and IHC Health Services, Inc., dated November 19, 2020. Exhibit 10.19 Execution Version FIRST AMENDMENT TO REPURCHASE PROMISSORY NOTE ? This FIRST AMENDMENT TO REPURCHASE PROMISSORY NOTE dated as of November 19, 2020 (this ?Amendment?) is by and among P3 HEALTH GROUP HOLDINGS, LLC, a Delaware limited liability company (the ?Company?), and IHC Health Services, Inc. (?Holder?). ? WHEREAS, the Company executed and delivered that certain Repurchase Promiss
October 21, 2022	EX-4.4	Description of Registered Securities (incorporated by reference to Exhibit 4.4 to the registrant’s Annual Report on Form 10-K filed on October 21, 2022). Exhibit 4.4 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED The following description of the capital stock of P3 Health Partners, Inc. (the ?Company?, ?we?, ?us?, and ?our?) and certain provisions of our second amended and restated certificate of incorporation (the ?Charter?) and amended and restated bylaws (the ?Bylaw
October 21, 2022	EX-10.20	Second Amendment to Term Loan Agreement and First Amendment to Security Agreement, dated as of December 21, 2021, by and among P3 Health Group, LLC, as borrower, the Subsidiary Guarantors party thereto and CRG Servicing LLC, as administrative agent and collateral agent. ? Exhibit 10.20 SECOND AMENDMENT TO TERM LOAN AGREEMENT AND FIRST AMENDMENT TO SECURITY AGREEMENT THIS SECOND AMENDMENT TO TERM LOAN AGREEMENT AND FIRST AMENDMENT TO SECURITY AGREEMENT (this ?Agreement?), dated as of December 21, 2021, is entered into among P3 HEALTH GROUP, LLC, a Delaware limited liability company (?Borrower?) (formerly known as FAC MERGER SUB LLC, successor by merger to P3 HEALT
October 21, 2022	EX-10.25	Non-Employee Director Compensation Program. Exhibit 10.25 P3 HEALTH PARTNERS, INC. DIRECTOR COMPENSATION PROGRAM Eligible Directors (as defined below) on the board of directors (the ?Board?) of P3 Health Partners, Inc. (the ?Company?) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this ?Program?). The cash and equity compensation described in this Program shall be p
October 21, 2022	EX-10.18	Repurchase Promissory Note between P3 Health Group Holdings, LLC and IHC Health Services, Inc., dated June 28, 2019. Exhibit 10.18 Execution Version THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR THE SECURITIES LAWS OF ANY STATE, AND HAS BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF
October 21, 2022	EX-10.11	First Amendment to the P3 Health Partners Inc. 2021 Incentive Award Plan. Exhibit 10.11 AMENDMENT TO THE P3 HEALTH PARTNERS, INC. 2021 INCENTIVE AWARD PLAN THIS AMENDMENT (the ?Amendment?) to the P3 Health Partners, Inc. 2021 Incentive Award Plan (the ?Plan?), is made and adopted by the Board of Directors (the ?Board?) of P3 Health Partners, Inc. (the ?Company?), effective as of March 24, 2022 (the ?Effective Date?). All capitalized terms used but not otherwise defined
October 21, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
October 21, 2022	EX-21.1	List of Subsidiaries (incorporated by reference to Exhibit 21.1 to the registrant’s Annual Report on Form 10-K filed on October 21, 2022). Exhibit 21.1 Subsidiaries of the Registrant ? ? ? ? ? ? ? Entity Name DBA Jurisdiction of Organization P3 Health Group, LLC ? P3 Health Group, LLC ? Delaware ? P3 Health Group Consulting, LLC ? P3 Health Group Consulting, LLC ? Delaware ? P3 Health Group Management, LLC ? P3 Health Group Management, LLC ? Delaware ? P3 Health Partners, LLC ? P3 Health Partners, LLC ? Delaware ? P3 Health Partners-
October 20, 2022	8-K/A	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 18, 2022 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction (Commissio
October 20, 2022	EX-99.1	P3 Health Partners Provides Second-Quarter and Year-to-Date 2022 Financial Results Increases 2022 Revenue Outlook Exhibit 99.1 P3 Health Partners Provides Second-Quarter and Year-to-Date 2022 Financial Results Increases 2022 Revenue Outlook • Strong First-Half 2022 revenue growth of 84% compared to the First-Half 2021 • At-risk Medicare Advantage members exceeded 100,000 at the end of the First Half of 2022 • Net loss PMPM increased to $1,580 in the First Half of 2022 from $135 in the First Half of 2021, prim
October 20, 2022	S-8 POS	As filed with the Securities and Exchange Commission on October 20, 2022 ?As filed with the Securities and Exchange Commission on October 20, 2022 Registration No.
October 20, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 14, 2022 P3 Health Partne UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 14, 2022 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction (Commission (I.R.S. Employer
October 19, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 18, 2022 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction (Commission (I.R.S. Employer
October 4, 2022	EX-99.1	P3 Health Partners Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company’s Securities The Company Intends to Submit All Periodic Reports a Exhibit 99.1 P3 Health Partners Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company?s Securities The Company Intends to Submit All Periodic Reports and Hold an Earnings Call the Week of October 17, 2022 Henderson, NV, October 4, 2022 (Business Wire) ? P3 Health Partners Inc. (?P3? or t
October 4, 2022	8-K	Regulation FD Disclosure, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 28, 2022 P3 Health Partners Inc. (Exact name of registrant as specified in its charter) Delaware 001-40033 85-2992794 (State or other jurisdiction (Commission (I.R.S. Employ
September 12, 2022	SC 13D	PIII / P3 Health Partners Inc - Class A / Leavitt Equity Partners II, L.P. - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) P3 Health Partners Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 744413 105 (CUSIP Number) Taylor Leavitt Managing Partner and Chief Executive Officer Leavitt Equity Partners II, L.P. 299 South Main
September 12, 2022	EX-99.1	JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) This joint filing agreement is made pursuant to Rule 13d-l(k)(1) under the Securities and Exchange Act of 1934, as amended (the “Act”), by and among the parties listed below, each referenced to herein as a “Joint Filer”. The Joint Filers agree that a statement of beneficial ownership as required by Sections 13(g) or 13(d) of the Act and

PIII / P3 Health Partners Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)